# Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

> **NCT00617344** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 260 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever
- Dengue Virus

## Interventions

- **BIOLOGICAL:** Tetravalent CYD Dengue Vaccine , 5555 formulation
- **BIOLOGICAL:** Tetravalent CYD Dengue Vaccine , 5553 formulation
- **BIOLOGICAL:** Tetravalent CYD Dengue Vaccine, 4444 formulation

## Key facts

- **NCT ID:** NCT00617344
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-17
- **Primary completion:** 2009-12
- **Final completion:** 2010-02
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2019-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617344, "Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00617344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*